Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trastuzumab deruxtecan + afatinib
- Development stage
- Phase 2
- Lead developer
- Daiichi Sankyo
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Trastuzumab deruxtecan + afatinib is an investigational combination therapy being evaluated for the treatment of HER2-low advanced or metastatic gastric cancer and gastroesophageal junction (GEJ) adenocarcinoma. This regimen combines trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate (ADC) targeting HER2 with a topoisomerase I inhibitor payload, and afatinib, an irreversible tyrosine kinase inhibitor (TKI) of the ErbB receptor family (EGFR, HER2, and ErbB4). The combination is the focus of the VIKTORY-2 clinical trial, led by researcher Jeeyun Lee, which aims to investigate whether dual blockade of the HER2 pathway can improve clinical outcomes in patients with low HER2 expression who have progressed on prior therapies. T-DXd is developed by Daiichi Sankyo and AstraZeneca, while afatinib is a product of Boehringer Ingelheim.
- Other names
- T-DXd + afatinibtrastuzumab deruxtecan and afatinib
02
Targets
EGFR (Epidermal growth factor receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)ERBB4 (Erb-b2 receptor tyrosine kinase 4)
Beyond the preview
Go deeper on trastuzumab deruxtecan + afatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trastuzumab deruxtecan + afatinib.